Bumrungrad Hospital (BH) Q3 2025 earnings summary

Executive summary

• Q3 2025 delivered strong performance with net profit up 4.1% and EBITDA up 5.5% year-over-year, driven by international patient growth, especially from the Middle East and South Asia.

• Non-Thai revenue reached a record 67% of total, offsetting declines from China and Cambodia.

• The hospital received multiple awards for excellence and innovation, including Best Public Company in Health Sector and recognition for patient experience.

• Major campus and hospital expansion projects, including BIH Phuket and new oncology institute, are on target.

• Interim financials for the three- and nine-month periods ended 30 September 2025 were reviewed with no material misstatements found.

Financial highlights

• Q3 2025 total revenue rose 2.1% year-over-year to THB 6,582 million; net profit was THB 2,035 million, up 4.1%.

• EBITDA for Q3 2025 was THB 2,731 million (+5.5% YoY); EBITDA margin reached 41.5%, and net profit margin hit a record 30.9%.

• For the nine months, total revenue declined 2.3% year-over-year to THB 18,890 million, with net profit down 4.2% to THB 5,626 million.

• Cash and investments increased to THB 15,242 million, supported by strong operating cash flow and receivables collection.

• Basic EPS for Q3: THB 2.56 (2024: THB 2.46); diluted EPS: THB 2.35 (2024: THB 2.25).

Outlook and guidance

• Q4 2025 is tracking equal to or better than Q3, with a cautiously optimistic outlook for year-end.

• Continued momentum expected from international markets, especially Middle East and South Asia.